Cantor Fitzgerald Reaffirms “Overweight” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Cantor Fitzgerald restated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $7.00 price target on the stock.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday. Chardan Capital reissued a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group reduced their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Down 9.3 %

NASDAQ TSHA opened at $2.06 on Tuesday. The firm’s fifty day moving average price is $1.98 and its 200 day moving average price is $2.38. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The company has a market capitalization of $422.18 million, a price-to-earnings ratio of 3.27 and a beta of 0.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TSHA. Creative Planning purchased a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $28,000. Principal Financial Group Inc. acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at about $48,000. China Universal Asset Management Co. Ltd. grew its position in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after buying an additional 17,446 shares during the period. Intech Investment Management LLC purchased a new position in Taysha Gene Therapies in the third quarter valued at about $85,000. Finally, Scientech Research LLC purchased a new position in Taysha Gene Therapies in the second quarter valued at about $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.